These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Combined cyclophosphamide, vincristine, doxorubicin, and prednisone (CHOP) improves response rates but not survival and has lower hematologic toxicity compared with combined mitoxantrone, chlorambucil, and prednisone (MCP) in follicular and mantle cell lymphomas: results of a prospective randomized trial of the German Low-Grade Lymphoma Study Group. Nickenig C; Dreyling M; Hoster E; Pfreundschuh M; Trumper L; Reiser M; Wandt H; Lengfelder E; Unterhalt M; Hiddemann W; Cancer; 2006 Sep; 107(5):1014-22. PubMed ID: 16878325 [TBL] [Abstract][Full Text] [Related]
18. The hyper-CVAD-rituximab chemotherapy programme followed by high-dose busulfan, melphalan and autologous stem cell transplantation produces excellent event-free survival in patients with previously untreated mantle cell lymphoma. Ritchie DS; Seymour JF; Grigg AP; Roberts AW; Hoyt R; Thompson S; Szer J; Prince HM Ann Hematol; 2007 Feb; 86(2):101-5. PubMed ID: 17089127 [TBL] [Abstract][Full Text] [Related]
19. Mantle cell lymphoma of the iris. Economou MA; Kopp ED; All-Ericsson C; Seregard S Acta Ophthalmol Scand; 2007 May; 85(3):341-3. PubMed ID: 17488468 [No Abstract] [Full Text] [Related]
20. Rituximab and DHAP followed by intensive therapy with autologous stem-cell transplantation as first-line therapy for mantle cell lymphoma. de Guibert S; Jaccard A; Bernard M; Turlure P; Bordessoule D; Lamy T Haematologica; 2006 Mar; 91(3):425-6. PubMed ID: 16531272 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]